Blog: SELLAS LIFE SCIENCES GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –


On September 15, 2022, SELLAS Life Sciences Group, Inc. (the “Company”) hosted a
webinar with the Company’s investors. The slides from the webinar are included
as Exhibit 99.1 hereto and the transcript of the webinar is included as Exhibit
99.2 hereto.

The information disclosed under this Item 7.01, including Exhibits 99.1 and 99.2
hereto, are being furnished and shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be
incorporated by reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended, except as expressly set
forth in such filing.

The slides and the transcript contain forward-looking statements. Such
forward-looking statements can be identified by the use of the words “expect,”
“believe,” “will,” “anticipate,” “estimate,” “plan,” “project” and other words
of similar import. These forward-looking statements include, but are not limited
to, statements related to the potential commercial opportunity for the Company’s
clinical candidate, galinpepimut-S (GPS). These forward-looking statements are
based on current plans, objectives, estimates, expectations and intentions, and
inherently involve significant risks and uncertainties. Actual results and the
timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties, which
include, without limitation, risks and uncertainties associated with the
COVID-19 pandemic and its impact on the Company’s clinical plans and business
strategy, oncology product development and clinical success thereof, the
uncertainty of regulatory approval, and other risks and uncertainties affecting
SELLAS and its development programs. These risks and uncertainties are described
more fully under the caption “Risk Factors” in SELLAS’ Annual Report on Form
10-K filed on March 31, 2022 and in its other filings with the Securities and
Exchange Commission. Other risks and uncertainties of which SELLAS is not
currently aware may also affect SELLAS’ forward-looking statements. The
forward-looking statements herein are made only as of the date hereof. SELLAS
undertakes no obligation to update or supplement any forward-looking statements
to reflect actual results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of which the
forward-looking statements were made.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

Number                                  Description
  99.1      Corporate Presentation for September 15, 2022 Webinar
  99.2      SELLAS Life Sciences Group, Inc. Transcript of Investor Webinar,
          dated September 15, 2022
104       Cover Page Interactive Data File (embedded within the Inline XBRL

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s